Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
47.20
+0.70 (1.51%)
At close: Jan 23, 2026, 4:00 PM EST
47.30
+0.10 (0.21%)
After-hours: Jan 23, 2026, 7:48 PM EST
Sanofi Revenue
Sanofi had revenue of 13.17B EUR in the quarter ending September 30, 2025, with 1.49% growth. This brings the company's revenue in the last twelve months to 45.93B, up 4.55% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 6.41% growth.
Revenue (ttm)
45.93B EUR
Revenue Growth
+4.55%
P/S Ratio
2.09
Revenue / Employee
554,200 EUR
Employees
82,878
Market Cap
112.73B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 64.24B |
| Pfizer | 62.79B |
| AbbVie | 59.64B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Bristol-Myers Squibb Company | 48.03B |
| GSK plc | 43.24B |
SNY News
- 1 day ago - Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema - WSJ
- 1 day ago - Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis - GlobeNewsWire
- 9 days ago - Press Release: Myqorzo and Redemplo approved in China - GlobeNewsWire
- 9 days ago - Sanofi sees softness in U.S. vaccine demand in near term - Reuters
- 9 days ago - Sanofi: Information concerning the total number of voting rights and shares - December 2025 - GlobeNewsWire
- 11 days ago - Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi - GlobeNewsWire
- 12 days ago - Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes - GlobeNewsWire